Global Blood Therapeutics (GBT) Misses Q4 EPS by 6c, Revenues Beat

Global Blood Therapeutics (NASDAQ: GBT) reported Q4 EPS of ($1.00), $0.06 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $39.03 million.

“In 2020, GBT adapted to the challenging conditions of the global COVID-19 pandemic to safely and successfully execute the launch of Oxbryta. It is a testament to our team’s dedication and the need for innovative therapies for sickle cell disease that we ended the year with thousands of patients on Oxbryta, an established base of prescribers, broad payer coverage, and a growing body of real-world evidence demonstrating statistically significant decreases in VOCs and transfusions and improved overall health-status. In addition, we announced robust progress for our pipeline with plans to advance inclacumab and GBT601 in 2021. We believe both these programs have the potential to become best-in-class SCD therapies, further expanding our leadership in SCD,” said Ted W. Love, M.D., president and CEO of GBT.

“We continue to be confident in the long-term potential of Oxbryta and are well positioned to build on our strong fundamentals to enhance our commercialization efforts in the U.S. and accelerate adoption. Furthermore, we continue to make important progress on our goal to provide access to Oxbryta to more SCD patients. We will also continue to support the SCD community and efforts to improve access to care, which has become even more important because of the impact of the COVID-19 pandemic that has dramatically magnified long-standing health inequities,” added Dr. Love.

For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Evogene chairman to address dissident shareholders on results call
• Reading (RDI) Tops Q2 EPS by 4c